1. Pink Sheet

Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal

 
• By Kevin Grogan

The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.

queue
Ipsen sold the PRV received with the approval of Sohonos. • Source: Shutterstock

Ipsen SA appears to have reset the market for US Food and Drug Administration priority review vouchers after selling its voucher to an unnamed company for $158m.

Ipsen received the voucher, which can be used to shorten the FDA review time for a new drug from 10 months to six months after the 60-day filing review, following FDA approval of Sohonos (palovarotene) in August 2023 as the first approved treatment for fibrodysplasia ossificans progressive (FOP)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Pink Sheet

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.